Comparing two medicines for hallucinations in Parkinson's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study compares two drugs, pimavanserin and quetiapine, to see which works better for hallucinations or delusions caused by Parkinson's disease. The goal is to help patients manage these symptoms more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a veteran.
- You have Parkinson's disease and experience hallucinations or delusions.
- Your Parkinson's medications have been stable for at least 2 weeks before the study.
- You have a caregiver or family member who can attend study visits with you.
- You speak English.
- You have not taken pimavanserin in the last 3 months, or quetiapine above 50 mg/day, or any antipsychotic in the past week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines—quetiapine and pimavanserin—in people with psychosis caused by Parkinson’s disease or Lewy body dementia, looking at how they work over time. You might join if you are starting an antipsychotic for the first time and your clinician can safely manage either option.
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
This study uses a special PET brain scan tracer to better understand serotonin receptor activity in people with certain neurodegenerative conditions, especially when they develop hallucinations or delusions. The results may help researchers improve how these brain changes are measured and tracked over time.
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
This trial tests if pimavanserin can reduce impulse control disorders like gambling, shopping, hypersexuality, or overeating in people with Parkinson's disease. It aims to help those whose symptoms are moderate but not too severe.
This study looks at how your past experiences and expectations might influence visual hallucinations if you have Parkinson's disease. It involves cognitive tests and compares people with and without hallucinations, as well as healthy volunteers.
Hear when a new Parkinson's Disease Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.